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Abstract
Emerging sexually transmitted hepatitis C virus (HCV) epidemics among men who have sex
with men (MSM) have been reported worldwide, with higher HCV infection rates among
those who are HIV-infected. This study aims to determine prevalence of recent and chronic
HCV infections among community-recruited MSM in New York City (NYC), map HCV infec-
tions by home, social, and sexual neighborhoods, and identify clusters of genetically linked
HCV variants using phylogenetic analysis. The NYC M2M study recruited MSM via modified
time-space, venue-based sampling and internet/mobile app-based recruitment during
2010–13. Participants completed a Google Earth map on neighborhoods of where they
lived, socialized, and had sex in the last 3 months, an ACASI questionnaire, and a sexual
network inventory about their sex partners. The men received HIV testing and provided
serum samples. Testing on stored serum samples included HCV antibody and RNA viral
load, HCV antibody avidity assay (avidity index <30% with positive viral load is considered
recently infected), and HCV RNA extraction and amplification to generate a 432 base-pair
region of Core/E1 for sequencing and phylogenetic analysis. Historic local controls were
included in the phylogenetic analysis. Of 1,028 MSM, 79.7% were HIV-negative and 20.3%
HIV-positive. Twenty nine MSM (2.8%) were HCV antibody-positive. MSM who were HCV
antibody-positive reported a median of 2 male sex partners in last 3 months, with 6.9% aged
18–24, 17.2% 25–29, 13.8% 30–39, and 62.1% 40 and over. 8.1% of HIV-positive MSM
were HCV antibody-positive vs. 1.5% of HIV-negative men (p<0.0001). Of 29 HCV-antibody
positive MSM, 12 (41%) were HCV RNA-positive (11 subtype 1a and 1 subtype 1b). Two of
12 HCV RNA-positive participants had low antibody avidity values, suggesting recent HCV
infection. HCV antibody seropositivity was significantly associated with older age >40 years,
adjusted odds ratio (aOR) 3.56 (95% CI 1.57, 8.08), HIV-positive serostatus, aOR 3.18
(95% CI 1.40, 7.22), any sexually transmitted infection (STI) in the last 3 months, aOR 2.81
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Mapping of HCV infections differed slightly by home, social, and sexual neighborhoods.
Based on phylogenetic analysis from 12 HCV RNA-positive samples, no evidence of a clus-
tered HCV epidemic was found. Overall HCV seroprevalence was 2.8% among community-
recruited MSM in NYC, with higher prevalence among HIV-positive MSM compared to HIV-
negative MSM. Only two participants were found to have recent HCV infection, with no evi-
dence of a clustered HCV epidemic based on phylogenetic analysis. Our results support
testing of HCV infection among HIV-negative MSM if they report having a recent STI and
IDU in the past rather than universal HCV testing in all HIV-negative MSM.
Introduction
Although primary transmission of hepatitis C virus (HCV) is through the parenteral route[1],
epidemics of sexually transmitted HCV infection among men who have sex with men (MSM)
have been reported in Europe, Australia, Asia, and North America, with blood remaining the
likely medium for sexual transmission of HCV in these outbreaks[2–14]. These sexually trans-
mitted HCV outbreaks have mostly involved HIV-infected MSM, with lower HCV infection
rates in HIV-negative MSM[13, 15–26]. Many studies have also reported strong associations
between HCV infection risk and sexual risk behaviors, including high number of sexual part-
ners[10, 27], condomless anal sex[10, 11, 17, 27], recreational drug use during sex[10, 11], and
traumatic sexual practices such as fisting[10, 27, 28]. In the Multicenter AIDS Cohort Study
(MACS) study of HCV infections among HIV positive and HIV negative MSM in four U.S.
metropolitan areas from 1984–2011, 115 cases of incident HCV infection were reported (inci-
dence rate of 2.08/1,000 person-years [PYs]). In multivariate analysis, condomless receptive
anal sex with more than one male partner, older age, HIV infection, heavy alcohol use, hepati-
tis B surface antigen positivity, and syphilis infection were significantly associated with inci-
dent HCV infection[17]. High rates of HCV reinfection of up to 15/100 PYs have been
reported among HIV-infected MSM who had previously received successful HCV treatment
or had spontaneously cleared their HCV infections[29–32].
Untreated HCV infection leads to chronic hepatitis in 60–80% of cases. Spontaneous clear-
ance of HCV without treatment is seen in approximately 25% of exposed individuals in the
first 6 months. Serious complications of chronic hepatitis include liver cirrhosis and hepatocel-
lular carcinoma[1, 33–37]. With the introduction of new, oral direct acting antiviral drugs,
treatment success rates for chronic HCV infection have improved markedly[38–40]. Inter-
feron-based HCV treatment early after diagnosis is associated with higher rates of sustained
virologic response compared to delayed treatment of chronic HCV infection[41–44], with the
use of direct acting antiviral drugs under investigation for recent HCV infection. Early treat-
ment has public health implications by potentially decreasing the risk of onward sexual and
parenteral transmission of HCV to partners. Cost-effectiveness studies show that early HCV
treatment after diagnosis maximizes medical costs savings and gains in quality-adjusted life
years[45–47].
Given the benefits of early compared to late HCV treatment, accurate diagnosis of recent
HCV infection is important. Clinical diagnosis of recent HCV infection can be challenging
since newly infected individuals are frequently asymptomatic[48]. Diagnosis can also be
delayed and problematic, as it can be difficult to distinguish between acute, resolved, and
chronic infections when using immunoglobulin M (IgM) anti-HCV testing[48, 49].HCV anti-
body avidity assays are research tools that measure the binding strength of anti-HCV
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antibodies in infected individuals. These assays can be used in research to distinguish recent
infection from chronic and resolved HCV infections[48, 50–56]. HCV antibody avidity
increases gradually over the course of HCV infection: antibodies produced early in infection
have weak antigen-binding ability while mature antibodies generated later in infection have
strong antigen-binding capacity. HCV antibody avidity assays can provide advantages over
traditional laboratory diagnosis of recent HCV infection and can be important for estimating
HCV incidence using cross-sectional research data[55].
This study aims to determine prevalence of recent and chronic HCV infections among
community-recruited MSM in New York City (NYC) by using HCV antibody avidity assays,
determine sociodemographic and risk behavior characteristics that are associated with HCV
infection, map HCV infections by home, social, and sexual neighborhoods, and identify clus-
ters of genetically linked HCV variants using phylogenetic analysis. This study is based on the
NYC M2M study (NIH R01 HD059729, PI: Koblin), a cross-sectional study conducted
between 2010–2013 to identify urban environment characteristics that influence sexual risk
behaviors, substance use, and depression among 1,458 MSM in NYC[57–61].
Materials and methods
The NYC M2M study was approved by the Institutional Review Board (IRB) of the New York
Blood Center, and this identity unlinked substudy was also approved by the New York Blood
Center IRB. No new samples or behavioral data were acquired for this substudy. All laboratory
testing was performed in a research laboratory incapable of releasing results to patients or cli-
nicians. All participants in the NYC M2M study were contacted by study staff upon comple-
tion of laboratory analyses with a summary of study findings and referral to various clinics in
NYC for clinical HCV testing and medical management as needed.
As described in detail previously[58, 59], MSM from the main NYC M2M study were
recruited in person using a modified venue-based, time-space sampling methodology and
internet- and mobile application-based recruitment. They were eligible for the study if they
self-reported biological male sex at birth; engaged in anal sex with a man in the past 3 months;
at least 18 years of age; resided in New York City; communicated in English or Spanish; and
were willing and able to give informed consent for the study. Interested participants were
referred to the study website and screened for preliminary eligibility. Study staff made attempts
to contact preliminarily eligible participants to further screen for eligibility and schedule an
on-site study visit.
After providing written informed consent, participants completed the Neighborhood Loca-
tor Questionnaire (NLQ) with study staff. This questionnaire collected information on the
location of 4 neighborhoods: home (where they lived), social (where they socialized most
often) and sexual (where they most recently had sex and where they most often had sex in the
last 3 months). The men identified the neighborhoods by utilizing Google Earth on a computer
to ‘drop a pin’ at the closest intersection. Geospatial coordinates (latitude and longitude) of the
pin drop for each type of neighborhood were recorded. Next, the participants completed an
Audio Computer-Assisted Self-Interview Software (ACASI) questionnaire. Next, a social and
sexual network questionnaire (SSNQ) was completed with an interviewer with data entry into
a computer system. Participants were asked, using a name generator, to name up to 10 people
with whom they have had a social relationship and up to 15 sexual partners with whom they
have had anal or vaginal sex in the last 3 months.
Participants then received HIV risk reduction counseling and were offered a rapid HIV
antibody test (Orasure), with reactive HIV tests confirmed by Western Blot. Participants with
HIV infection (newly diagnosed and previously known infection) were asked to provide a
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blood sample to test for CD4 cell count and HIV viral load. A total of 10 mL blood sample was
collected from the participants. Participants testing HIV-positive were referred for treatment
and services. Participants who consented to blood storage had remaining serum samples ali-
quoted and stored frozen at -80˚C. Participants were reimbursed $50 and a Metrocard for
their time and transportation cost.
Laboratory analysis of serum samples
HCV antibody. HCV antibody testing was performed using the Genedia HCV ELISA 3.0
(Green Cross Medical Science, Korea) as per manufacturer’s protocol. Confirmatory Recombi-
nant ImmunoBlot Assay (RIBA) testing was not performed.
HCV RNA viral load. HCV RNA viral load testing was performed using the Abbott Real
Time HCV Amplification Reagent Kit (No. 04J86-90, Des Plaines, Illinois), with a limit of
detection of 50 IU/mL.
HCV antibody avidity assay. The identification of individuals with recent infection was
based on a HCV antibody avidity assay using diethylamine (DEA) as a chaotropic agent[55].
An avidity index was calculated by determining the percentage that the DEA reduces in optical
density of the sample in comparison to a paired non-treated well. An avidity index<30% was
considered recently infected. The algorithm for defining recent HCV infection was an avidity
index<30% and a positive HCV RNA viral load. We used a method where individuals
appeared recently infected for a mean of 147 days after seroconversion and< 1% of 579 chron-
ically infected individuals (>2 years post infection) were misclassified[55]. The false recent
rate used was 1.1%, properly adjusted for the HIV prevalence of the cohort[55].
HCV phylogenetics. HCV ribonucleic acid (RNA) was extracted and amplified to gener-
ate a 432 base-pair region of Core/E1 for sequencing. HCV genotype was determined. All
sequence data generated from participants, reference sequences for subtype 1a and 1b, and
unrelated sequences from NYC study of people who inject drugs[62] were used to generate a
maximum likelihood tree using PhyML with 200 bootstraps. Phylogenies were estimated using
a maximum likelihood approach and those sequences linked by nodes with bootstrap support
>70 considered clustered.
Measures
ACASI. Data on age, race/ethnicity, education, household income, and self-reported HIV
serostatus were collected via the ACASI questionnaire. Alcohol and drug use in the prior 3
months was also collected, including use of marijuana, inhaled nitrates, smoked and powder
cocaine, methamphetamine, heroin, non-prescribed hydrocodone bitartrate and acetamino-
phen/oxycodone/alprazolam, sildenafil/tadalafil /vardenafil, hallucinogens, injection drug use
(IDU), anabolic steroids and female hormones. In addition, IDU ever in the past was asked.
Self-reported history of sexually transmitted infections (STIs) in the last 3 months included
any genital or rectal gonorrhea or chlamydia infections, any genital or rectal herpes infection,
any syphilis infection, and any genital or rectal sores or discharge.
Network questionnaire. For the SSNQ, each participant was asked to name up to 10 per-
sons whom he could rely on for functional support using four domains. In addition, partici-
pants were asked about their partners with whom they had anal or vaginal sex in the last 3
months using a name generator with up to 15 sex partners. Detailed questions were asked
about each named sexual partner, including socio-demographics, partner type, where partici-
pant met the partner, frequency of anal or vaginal sex and condom use with sex with the part-
ner in the last 3 months, and specific drug or alcohol use during anal sex with or without
condom use in the last 3 months with the partner.
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Statistical methods
The participant’s HIV status was determined by a combination of the self-reported HIV status
on ACASI questionnaire and HIV test result (positive, negative, indeterminate) at the site. If a
participant self-reported being HIV-positive but deferred or refused an HIV test at the study
visit, he was categorized as HIV-positive. If a participant self-reported being HIV-negative or
unknown status but tested HIV-positive on the HIV test, he was categorized as HIV-positive
for this analysis.
HCV infections based on laboratory testing on stored serum samples of NYC M2M partici-
pants were classified as follows: (1) recent HCV infection (HCV antibody and RNA positive,
and recent infection by HCV antibody avidity assay), (2) chronic HCV infection (HCV anti-
body and RNA positive, no recent infection by HCV antibody avidity assay), (3) resolved
HCV infection with clearance (HCV antibody positive, RNA negative; either those who were
successfully treated for HCV infection or had spontaneously cleared HCV), and (5) no HCV
exposure. Prevalence of HCV antibody seropositivity (recent, chronic, and resolved HCV
infections) was computed and stratified by HIV serostatus (positive, negative/indeterminate)
based on testing and self-report at the study visit; 95% confidence intervals (CI) were
calculated.
To determine factors that were independently associated with HCV antibody seropositivity
(recent, chronic, and resolved HCV infections) among MSM in NYC, the following variables
were included: sociodemographics (age, race/ethnicity, education, annual household income,
employment), HIV serostatus, history of IDU in last 3 months and ever in the past, general
alcohol use, IDU and non-IDU [from ACASI], self-reported STIs [from ACASI], alcohol and
substance use during condomless sex [from SSNQ], and sexual risk behaviors such as number
of male, transgender, and female partners, having an anonymous sex partner, having a sex
partner met on the internet or mobile application, any condomless insertive anal intercourse
with a male partner, and any condomless receptive anal intercourse [all from SSNQ]. Differ-
ences in HCV seropositivity were compared by sociodemographic, HIV serostatus, and risk
behavior variables using Chi-square or Fisher’s exact tests. Characteristics that were significant
with p-value0.10 in the Chi-square or Fisher’s exact tests were included in multivariable
logistic regression models to determine factors associated with having HCV seropositivity. A
forward selection process was used to identify variables to include in the final multivariable
models. A two-sided p-value0.05 was considered statistically significant. All data analyses
were conducted in SAS version 9.3 (SAS Institute Inc., Cary, NC, USA).
To map HCV antibody seropositivity (recent, chronic, and resolved HCV infections) by
home, social, and sexual neighborhoods among MSM in NYC, the 4 neighborhoods (home,
social, sexual with most frequent sex and last sex) collected from the NLQ of each participant
with HCV infection was assigned to a neighborhood tabulation unit (NTA), which are census
tract aggregations to the level of neighborhood or multiple neighborhoods currently used by
the NYC Department of City Planning. Study data were imported into ArcGIS (ESRI 2012.
ArcGIS Desktop: Release 10.1. Redlands, CA: Environmental Systems Research Institute) and
used to map the HCV seroprevalence data. ArcGIS shapefiles for the NYC community district
boundaries, water and non-residential areas were downloaded from NYC BYTES of the BIG
APPLE™ (http://www.nyc.gov/html/dcp/html/bytes/dwndistricts.shtml#bcd).
To determine clusters of genetically linked HCV variants among recently and chronically
HCV-infected MSM in NYC using phylogenetic analysis, HCV genotypes of recently and
chronically HCV-infected individuals were determined based on alignment of Core/E1 poly-
merase chain reaction (PCR) fragment 432 basepairs. Nucleotide Pairwise Distance (NPD)
was performed in Geneious and included reference sequences for subtype 1a and 1b using 21
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sequences sampled in NYC from 2001–2005[62, 63]. A phylogenetic tree was created using
maximum likelihood estimates to identify clusters of genetically linked HCV variants. Phylog-
enies were estimated using a maximum likelihood approach and those sequences linked by
nodes with bootstrap support >70 considered clustered.
Results
Of 1,458 men enrolled in the NYC M2M study between 2010 and 2013, 1,030 (71%) consented
to serum storage. Excluding two samples with insufficient serum volume for HCV lab analysis,
1,028 men were included. Of these 1,028 men, 79.7% were HIV-negative and 20.3% HIV-posi-
tive by testing and self-report (Table 1); 62 (6%) refused HIV testing, of whom 42% (26/62)
self-reported being HIV-positive. Of 1,028 men tested, 29/1028 (2.8%) were HCV antibody-
positive. Of these 29 who were HCV antibody-positive, 12/29 (41%) were HCV RNA-positive
(11 subtype 1a and 1 subtype 1b). Two of 12 HCV RNA-positive participants had low antibody
avidity values, suggesting recent HCV infection. Table 1 shows the HCV infection outcomes
based on testing, stratified by HIV serostatus by testing and self-report at the NYC M2M study
visit.
Table 2 compares the sociodemographic and risk behavior characteristics between the men
who had HCV antibody seropositivity and those who did not have seropositivity.
Those with HCV antibody seropositivity were more likely to be older, have lower education
level, have lower annual household income, not work full-time, be HIV-positive, not report
recent alcohol use, report IDU recently and ever in the past, and self-report recent STIs.
Based on multivariable logistic regression model, the following variables were significantly
associated with HCV antibody seropositivity: age>40 years vs. age 40 years), adjusted odds
ratio (aOR) 3.56 (95% CI 1.57, 8.08); HIV-positive serostatus (vs. HIV-negative/indeterminate
status), aOR 3.18 (95% CI 1.40, 7.22), any STI in the last 3 months, aOR 2.81 (95% CI 1.11,
7.13), and IDU ever, aOR 4.34 (95% CI 1.69, 11.17).
Fig 1 depicts the maps of HCV seroprevalence by neighborhoods at the NTA level, with
home (where the men live), social (where the men socialize), and sexual neighborhoods
(where they most often have sex in the last 3 months and where they most recently had sex).
NTAs in solid colors represent number of HCV seroprevalence as indicated in the legend of
each map, while NTAs outlined in red and blue depict recent and chronic HCV infections,
respectively. HCV seropositivity was found in all five NYC boroughs, with most concentrated
in mid/lower Manhattan for home, social, and sexual neighborhoods. The two recent HCV
infections were detected in two different NTAs in Brooklyn for home neighborhoods, with
change to Brooklyn, Manhattan, and Bronx NTAs for social and sexual neighborhoods.
Fig 2 depicts the phylogenetic tree comparing sequence data generated from the 11 NYC
M2M participants with subtype 1a HCV infection (labelled “NYC” and in red) and 1 NYC
Table 1. HCV infection outcomes based on HIV status, N = 1,028.
HCV Infection Outcome Overall N HIV-positive HIV-negative/indeteminate P-value
N (%) N (%)
Recent 2 2 (100.0) 0 (0.0) <0.001
Chronic 10 8 (80.0) 2 (20.0)
Resolved 17 7 (41.2) 10 (58.8)
No HCV exposure 999 192 (19.2) 807 (80.7)
Total 1,028 209 (20.3) 819 (79.7)
HIV serostatus based on HIV self-report at study visit
Chi-square test recent/chronic/resolved and no infection test of association with HIV status
https://doi.org/10.1371/journal.pone.0200269.t001
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Table 2. Sociodemographic and risk behavior characteristics, N = 1,028.
HCV antibody
seropositivity
No HCV antibody
seropositivity
P-value Adjusted OR
(aOR)
(N = 29) (N = 999) (95% CI)
Sociodemographics
Age (years) <0.0001
18–24 2 (6.9) 264 (26.4) -
25–29 5 (17.2) 276 (27.6) -
30–39 4 (1.8) 238 (23.8) -
40+ 18 (62.1) 221 (22.1) 3.56 (1.57, 8.08)
Race/ethnicity 0.45 -
Hispanic 11 (37.9) 300 (30.1)
Black Non-Hispanic only 8 (27.6) 231 (23.2)
White Non-Hispanic only 9 (31.0) 346 (34.7)
Mixed race or other 1 (3.5) 120 (12.0)
Education 0.04 -
Less than high school graduate 4 (13.8) 49 (4.9)
High school graduate 6 (20.7) 113 (11.3)
Some college 9 (31.0) 325 (32.5)
College graduate or more 10 (35.5) 512 (51.3)
Annual household income 0.004 -
< $10,000 10 (37.0) 160 (16.7)
$10,000 - < $40,000 12 (44.4) 370 (38.6)
$40,000 - < $60,000 5 (18.5) 254 (26.5)
 $60,000 0 (0.0) 175 (18.3)
Employment 0.0005 -
Working full-time 9 (31.0) 423 (42.3)
Working part-time 4 (13.8) 234 (23.4)
Not working but looking 5 (17.2) 191 (19.1)
Not working, not actively looking 6 (20.7) 41 (4.1)
Other 5 (17.3) 110 (11.0)
HIV serostatus based on HIV testing and self-report <0.0001
Positive 17 (58.6) 192 (19.2) 3.18 (1.40, 7.22)
Negative 12 (41.4) 765 (76.6) -
Indeterminate 0 (0.0) 42 (4.2) -
Risk behaviors
General alcohol use in last 3 mos. 22 (75.9) 919 (92.0) 0.008 -
Substance use in last 3 mos. 22 (75.9) 721 (72.2) 0.83 -
Injection drug use ever 8 (27.6) 45 (4.5) <0.0001 4.34 (1.69, 11.17)
Injection drug use in last 3 mos. 2 (7.1) 5 (0.5) 0.014 -
Alcohol and/or substance use during condomless sex in last 3 mos. 9 (31.0) 342 (34.2) 0.84 -
Self-reported STIs 8 (27.6) 75 (7.5) 0.001 2.81 (1.11, 7.13)
Median number of sex partners in last 3 mos. (IQR) -
Male partners 2 (1, 4) 3 (1, 4) 0.50
Transgender partners 0 (0, 0) 0 (0, 0) 0.57
Female partners 0 (0, 0) 0 (0, 0) 0.66
Any anonymous sex partner in last 3 mos. 10 (35.5) 313 (31.3) 0.69 -
Any sex partner met on the internet or mobile application in last 3
mos.
16 (55.2) 623 (62.4) 0.44 -
(Continued)
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M2M participant with subtype 1b HCV infection (labelled “NYC” and in green), as well as ref-
erence sequences for subtype 1a and 1b including 21 sequences sampled in NYC from 2001–
2015 from Kuntzen et al[62]. The average nucleotide pairwise distance (NPD) among 11 NYC
M2M study subtype 1a was 90.1%; the average NPD among Kuntzen et al. subtype 1a was
89.4%; the average NPD among Kuntzen et al. subtype 1b was 92%. The average NPD among
NYC M2M study and Kuntzen et al. subtype 1a was 90.2%, while the average NPD among
NYC M2M study subtype 1b and Kuntzen et al. subtype 1b was 89.9%. The two recent HCV
infections in the NYC M2M study (denoted with italics) were not clustered together.
Discussion
This study involving a large sample of community-recruited HIV negative and HIV positive
MSM in NYC found an overall HCV seroprevalence of 2.8%. The community-recruited sam-
ple had a low prevalence of individuals who reported injecting drugs ever in the past of 5.2%,
although they did report sexual risk behaviors that would place them at risk for sexual trans-
mission of HCV, with 14.2% of the MSM reporting any condomless insertive anal sex and
16.8% reporting any condomless receptive anal sex with a male partner in the last 3 months.
We found a higher HCV prevalence among HIV-positive MSM compared to HIV-negative
MSM (8.1% vs. 1.5%, respectively, p =<0.001), consistent with previously published data
showing higher rates of HCV infection among HIV-infected compared to uninfected MSM
[13, 15–25]. Of the 29 men who were HCV antibody-positive in our study, only 12 or 41%
were HCV RNA-positive, indicating chronic hepatitis C infection. Our HCV seroprevalence
of 8.1% (17/209) among HIV-infected MSM is lower than what has been reported in the litera-
ture for NYC. In one study, the proportion of HCV infections among HIV-infected individu-
als in NYC who are MSM dramatically increased from 7% in 2000 to 24% in 2010[64]. In
another NYC study from 1999–2007, 10.5% of HCV and HIV co-infected individuals were
found to be non-IDU MSM; this study had an older sample of individuals with mean age of
50.4 years[65]. These rates are markedly higher than those reported in other U.S. cities, includ-
ing San Francisco where HCV prevalence among non-IDU HIV-positive MSM decreased
from 9% in 2004 to 2% in 2011[66, 67].
In our study, using HCV antibody avidity testing, we detected recent HCV infection in
only two participants, with no evidence of a clustered HCV epidemic based on phylogenetic
Table 2. (Continued)
HCV antibody
seropositivity
No HCV antibody
seropositivity
P-value Adjusted OR
(aOR)
(N = 29) (N = 999) (95% CI)
Any condomless insertive anal intercourse with a male partner in last 3
mos.
6 (20.7) 141 (14.1) 0.29 -
Any condomless receptive anal intercourse with a male partner in last
3 mos.
7 (24.1) 166 (16.6) 0.31 -
 HCV antibody seropositivity includes those with recent, chronic, and resolved HCV infections.
 Variables obtained from the sexual network inventory, all other variables obtained from ACASI.
aOR: adjusted odds ratio
95% CI: 95% confidence interval
STIs: sexually transmitted infections
IQR: interquartile range
https://doi.org/10.1371/journal.pone.0200269.t002
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analysis. This finding differs from a previous finding of an HCV epidemic cluster in NYC, per-
haps because our study encompassed a community-recruited sample of mostly HIV-unin-
fected MSM, with a proportion of HIV-infected MSM, whereas the other study focused solely
on HIV-infected MSM who reported no injection drug use. In the NYC study among HIV-
infected MSM using phylogenetic analysis, 74 cases of recent sexually acquired HCV infection
were reported from 2005–2010, with five clusters of genetically linked HCV strains docu-
mented among the men[11]. In this study, condomless receptive anal intercourse and sex
while high on methamphetamines were independent risk factors for recent HCV infection.
The predominant HCV subtype in our study was subtype 1a, followed by subtype 1b. Several
different HCV genotypes have been documented in sexual transmission among MSM. In the
NYC study described above, a vast majority (90%) of the sexually-transmitted HCV infections
among HIV-infected MSM were genotype 1a, with 6% being genotype 1b[11]. In a Dutch
cohort study among HIV-infected and uninfected MSM, most HCV infections were genotype
1, followed by genotype 4[68]. In another Dutch study among MSM attending an STI clinic
Fig 1. Maps of HCV infections by neighborhoods.
https://doi.org/10.1371/journal.pone.0200269.g001
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from 2007–2008, phylogenetic analysis demonstrated at least 4 distinct clusters of HCV infec-
tion, suggesting sexual transmission of HCV, with most of the HCV isolates being genotype 1a
(71%) and 4d (17%), with the remainder being 3a (8%) and 1b (4%)[16].
In multivariate analyses in our study, we found that HCV antibody seropositivity was sig-
nificantly associated having reported any STI in the last 3 months, along with older age, IDU
ever history, and HIV-positive serostatus. In contrast to other studies, methamphetamine use
was not significantly associated with HCV seropositivity. This may be due to a Type II error
given the low number of HCV antibody-positive participants found in our study. In a study
comparing prevalence of HCV infection among IDU MSM and non-IDU MSM in the Multi-
center AIDS Cohort Study, HCV antibody seroprevalence among IDU MSM was 42.9%, sig-
nificantly higher than 4.0% among non-IDU MSM; in addition, HCV clearance was lower
among IDU MSM compared to non-IDU MSM. In both IDU and non-IDU MSM, HIV infec-
tion, older age, and Black race were associated with higher HCV antibody seroprevalence. In
contrast, our study did not find race/ethnicity to be a significant factor, which may be due to a
Type II error given the low number of HCV antibody-positive participants found in our study.
In this same study, syphilis infection was associated with HCV seroprevalence among non-
IDU MSM only[69]. In the Swiss cohort study, past syphilis infection, along with inconsistent
condom use, was associated with a 2-fold increased odds of HCV seroconversion[2]. Although
annual HCV testing is recommended for HIV-positive MSM and those entering HIV care in
the U.S.[70], universal HCV testing for HIV-negative MSM is not currently recommended[18,
71]. In light of our study findings, we agree with annual testing of HCV infection among HIV-
positive MSM, given the higher rates of HCV infection seen among HIV-positive MSM com-
pared to HIV-negative MSM. Rather than universal HCV testing in all HIV-negative MSM,
we recommend testing of HCV infection among HIV-negative MSM if they report having a
recent STI and past IDU use.
A unique feature of our study was the use of the NLQ to map the geographic distribution of
HCV infections among MSM at the level of specific NYC neighborhoods in which the
Fig 2. Phylogenetic analysis.
https://doi.org/10.1371/journal.pone.0200269.g002
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individuals lived, socialized, and had sex. To date, epidemiologic research on the sexually
transmitted HCV epidemic among MSM in NYC has been based on health department sur-
veillance and vital statistics data[64] or on referral of suspected HCV infections in HIV-
infected MSM from physicians to an referral academic medical center[11]. Public health
department and vital statistics data often lack detailed information on where HCV infections
are occurring, such as specific NYC neighborhoods, to ascertain whether there is geographic
variance in HCV infections within NYC, while referral data are limited by selection bias and
by the exclusion of HIV- negative MSM. Although our study did not find evidence of a cluster
of recent HCV infections and the geographic distribution of HCV infections differed only
slightly based on home, social, and sexual neighborhoods, probably limited by small number
of detected HCV infections, we encourage future studies to examine not only home neighbor-
hoods but also social and sexual neighborhoods to help identify NYC areas with the highest
HCV prevalence to guide prioritization of HCV screening and prevention interventions. In
addition, by combining these studies with phylogenetic analysis to determine clusters of genet-
ically linked HCV infections, unexpected HCV transmission networks not recognized by geos-
patial mapping and behavioral data might be discovered.
There are limitations to this study. First, the mode of HCV acquisition, either via IDU, sex-
ual, or other means such as via blood product transfusions, could not be confirmed in our par-
ticipants, as the ACASI did not ask specific questions about HCV infection and mode of
acquisition. In addition, the ACASI and SSNQ did not specifically ask about use of sex toys,
fisting, or bleeding during sex, which have been reported to be associated with sexual transmis-
sion of HCV[10]. Second, our sample size, with a total of 1,028 participants, might have not
have been adequate and might have limited a full analysis of the factors associated with HCV
serostatus Third, we were not able to determine prevalence of HCV reinfection in our study
population; high rates of HCV reinfection have been reported among MSM, especially HIV-
infected MSM, in the literature[29–32]. In addition, in those MSM with HCV seropositivity
and undetectable HCV viral load, we were not able to differentiate between those with HCV
spontaneous clearance vs. successful HCV treatment, since HCV treatment history was not
specifically asked during the study. Though the use of a systematic sampling scheme in the
main NYC M2M study should minimize selection bias, the participants might not be represen-
tative of all MSM living in NYC, with high education level and low past injection drug use his-
tory reported in our sample as well as the inclusion criteria of the NYC M2M study specifying
that they had to report having anal sex in the last 3 months. In addition, the data might not be
generalizable to MSM living in other urban areas in the U.S. Furthermore, self-reported data
on the ACASI and data reported to interviewers on the SSNQ might not accurately reflect the
actual risk behaviors of the participant and of their partners as a result of socially desirable
responding. In addition, in this study we defined recent HCV infection using an HCV anti-
body avidity index <30% and a positive HCV RNA viral load. This definition is not supported
by all studies to date[56], though the implications on our findings are limited given the small
number of HCV RNA positive samples found in our study. Lastly, there are limitations inher-
ent to the statistical methodology, with cautious interpretation of findings suggested. The lack
of association with variables such as methamphetamine use and race/ethnicity might be due to
Type I and II errors resulting from the small number of HCV antibody seropositivity and rela-
tively small sample size.
Conclusions
In conclusion, in a large community recruited sample of HIV-negative and HIV-positive
MSM in NYC with low prevalence of IDU, overall HCV seroprevalence was 2.8%. A higher
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HCV prevalence was found among HIV-positive MSM compared to HIV-negative MSM. Of
the 29 men who were HCV antibody-positive in our study, 12 or 41% were HCV RNA-posi-
tive, indicating chronic HCV infection. Only 2 recent HCV infections were detected based on
HCV avidity testing, with no clustering of genetically linked HCV infections based on phylo-
genetic analysis. HCV antibody seropositivity was significantly associated having reported any
recent STI, older age, IDU ever history, and HIV-positive serostatus. Our results support test-
ing of HCV infection among HIV-negative MSM if they report having a recent STI and IDU
ever in the past rather than universal HCV testing in all HIV-negative MSM.
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